A Little Something

Wednesday August 1st, 2018

Increasing sales, improving balance sheet and declining stock price . . . another company that highlights the divergence between fundamentals and share price . . .

True the company is investing aggressively in R&D, and in the drug development space, this comes with significant risk, however with the price down nearly 50% from January, there is a chance that continued growth returns the share price to the mean for a return of 20-25%.

20180801 - CORT

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s